SNKTY Senetek plc featured news, full reports, and detailed charts
Senetek plc (SNKTY/SNKTY.OB) Wrap Up:
Senetek PLC, together with its subsidiaries, engages in developing technologies for the science of healthy aging, including skincare and dermatological therapeutics, erectile dysfunction, and nutrition. The company operates in two segments, Skincare and Pharmaceutical. The Skincare segment offers Pyratine-6, a second generation cytokinin for the treatment of aging skin; 4HBAP that completed clinical tests for the treatment of photodamaged skin and its effect on the reduction of erythema; and Kinetin, a first generation cytokinin that is a plant growth factor, which retards senescence of plants and delays age-related changes in cultured human skin cells. The Pharmaceutical segment offers Invi...www.senetekplc.com
8 Employees
Founded in 1983
Senetek plc (SNKTY:OTC Bulletin Board Market)
LAST $1.30 USD
CHANGE TODAY +0.01 0.78%
VOLUME 8.0K
As of 3:47 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Senetek plc (SNKTY)
|
OPEN
$1.30
|
PREVIOUS CLOSE
$1.29
|
|
|
DAY HIGH
$1.35
|
DAY LOW
$1.20
|
|
|
52 WEEK HIGH
10/5/09 - $1.51
|
52 WEEK LOW
12/16/08 - $0.83
|
|
|
MARKET CAP
9.9M
|
AVERAGE VOLUME 3 mo
6.4K
|
|
|
DILUTED EPS TTM
$-0.64
|
SHARES OUTSTANDING
7.6M
|
|
|
SNKTY Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SNKTY Top Compensated Officers
Mr. Frank J. Massino
Chairman and Chief Executive Officer
Age: 61
Total Annual Compensation: $384.2K
Mr. William F. O'Kelly
Chief Financial Officer, Chief Accounting Off...
Age: 52
Total Annual Compensation: $230.9K
Mr. Phillip Rose R.Ph.
Chief Operating Officer
Age: 55
Total Annual Compensation: $132.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Senetek plc (SNKTY)
Senetek Evaluates Strategic Options; Retains Miller Tabak
10/23/2009
Senetek PLC announced that it has reatined Miller Tabak + Co., LLC as exclusive financial advisor to assist the Board of Directors with a review of strategic options and development of a business plan to maximize the assets of the company. The Board intends to consider a full range of strategic alternatives, including a recapitalization, a sale or disposition of one or more corporate assets, a potential merger and/or a strategic business combination. While Miller Tabak will assist Senetek in this process, there is no assurance the Company will follow any of the recommendations. If the Board approves a definitive transaction or definitive plan of action, an announcement will be made.
Senetek plc, Annual General Meeting, Dec 14, 2009
10/20/2009
Senetek plc, Annual General Meeting, Dec 14, 2009, at 10:00 US Pacific Time. Location: Meritage Hotel, 875 Bordeaux Way, Napa, CA 94558, United States. Agenda: To re-elect Kerry Dukes as a Director; to receive the Company's annual accounts for the financial year ended December 31, 2008 together with the last director report and auditors report on those accounts; to appoint Macias Gini & O' Connell LLP and BDO Stoy Hayward as the company's independent auditors for the financial year ending December 31, 2009 at a remuneration to be determined by the directors; and to transact such other business as may properly come before the Annual General Meeting and any adjournments and postponements thereof.
Senetek plc Announces Earnings Results for the Second Quarter Ended June 30, 2009
08/14/2009
Senetek plc announced earnings results for the second quarter ended June 30, 2009. The company announced revenues for its fiscal second quarter ended June 30, 2009 were $424,000, compared with $461,000 in the quarter ended March 31, 2009 and $691,000 reported in the comparable prior year period ended June 30, 2008. Net loss for the quarter was $1.299 million or $0.17 per share, compared with net income of $257,000 or $0.03 per share in the second quarter of 2008. The company noted that net income for the prior year quarter ended June 30, 2008 included other income of $1.125 million from a previously announced settlement.
SNKTY Competitors
| Company | Last | Change |
| Ceragenix Pharmaceuticals Inc | $0.59 USD | 0.00 |
| Euoko Group Inc | $0.06 USD | 0.00 |
| Helix Biomedix Inc | $0.27 USD | 0.00 |
| NovaBay Pharmaceuticals Inc | $1.96 USD | +0.01 |
| Syntopix Group | 76.00 GBX | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SNKTY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.2x |
|
| Price/Book | 0.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
SNKTY |
||
|
SNKTY transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Senetek plc
More news for SNKTY
Senetek PLC Reports Third Quarter 2009 Financial Results
NAPA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY - News), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced revenues for its fiscal third quarter ended September 30, 2009 were $550,000, compared with $424,000 in the quarter ended June 30, 2009 and $483,000 reported in the comparable prior year period ended September 30, 2008. Net loss for the quarter was $1.251 million or $(0.16) per share, compared with net loss of $1.050 million or $(0.14) per share in the third quarter of 2008. Revenues from the Pyratine family of proprietary Cytokinin-based skincare products --PyratineXR(TM) and Pyratine-6(TM) -- totaled $67,000 in the third quarter of 2009 compared to $28,000 in the third quarter of 2008. Royalties on sales of monoclonal antibodies were $440,000, an increase from the $412,000 in monoclonal antibody royalties in the third quarter of 2008.Gross profit margin for the third quarter of 2009 showed an increase to 63% versus third quarter 2008 at 58% of revenue. Skincare gross profit rate for the three months ended September 30, 2009, increased to 93% from 77% for the three months ended September, 2008, due to sales of higher margin Pyratine-6 and PyratineXR products in the current quarter. Pharmaceutical gross profit was consistent at 55% for the three months ended September 30, 2009 and 2008.Senetek PLC continues to focus on sales of Pyratine-6 and PyratineXR while ...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 10-Q, Quarterly Report
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Some of the information in this Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "should," "expect," "anticipate," "potential," "believe," "estimate," "intends" and "continue" or similar words. You should read statements that contain these words carefully because they: (i) discuss management's expectations about Senetek's future performance; (ii) contain projections of its future operating results or of its future financial condition; or (iii) state other "forward-looking" information. There will be events in the future that the Company is not able to predict or over which it has no control, which may adversely affect its future results of operations, financial condition or stock price. The risk factors described in the 2008 Form 10-K, as well as any cautionary language in this Form 10-Q, provide examples of risks, uncertainties and events that may cause the Company's actual results to differ materially from the expectations described in its forward-looking statements. You should be aware that the occurrence of any of the risks, uncertainties, or events described in this Form 10-Q could seriously harm Senetek's business and that, upon the occurrence of any of these events, the price of its securities could decline. All forward-looking statements included in this Form 10-Q are based on information available to the Company on the date hereof. Senetek assumes no obligation to update any such forward-looking statements except as may be required in connection with future reports of the Company pursuant to the Securities Exchange Act of 1934. Company Overview Senetek PLC is a life sciences company engaged in the research, development and commerc...Click here to read the whole Article (external link)
Senetek PLC Engages Miller Tabak as Financial and Strategic Advisors
NAPA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY - News), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that it has engaged Miller Tabak + Co., LLC as exclusive financial advisor to assist the Board of Directors with a review of strategic options and development of a business plan to maximize the assets of the company. The Board intends to consider a full range of strategic alternatives, including a recapitalization, a sale or disposition of one or more corporate assets, a potential merger and/or a strategic business combination. While Miller Tabak will assist Senetek in this process, there is no assurance the Company will follow any of the recommendations. If the Board approves a definitive transaction or definitive plan of action, an announcement will be made.About Senetek PLC:Senetek PLC (OTCBB: SNKTY - News) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted i...Click here to read the whole Article (external link)
Senetek Implements New Corporate Communication Policy
NAPA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY - News), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that the Senetek Board of Directors has implemented a new Corporate Communication policy to insure that the highest standards of corporate governance are met and that full compliance with all public company regulations is in place. With this new policy the Board commits to insuring that all Senetek investors as well as the general public are kept current with all pertinent Company business matters as it relates to its securities.On advice from corporate counsel, all future communications from the Company will be exclusively from press releases, SEC filings relating to events significant to Senetek business and from shareholder teleconferences addressing business updates.About Senetek PLC:Senetek PLC (OTCBB:SNKTY - News) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations ...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for SENETEK PLC /ENG/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for SENETEK PLC /ENG/ 31-Aug-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for infor...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 10-Q, Quarterly Report
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Some of the information in this Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "should," "expect," "anticipate," "potential," "believe," "estimate," "intends" and "continue" or similar words. You should read statements that contain these words carefully because they: (i) discuss management's expectations about Senetek's future performance; (ii) contain projections of its future operating results or of its future financial condition; or (iii) state other "forward-looking" information. There will be events in the future that the Company is not able to predict or over which it has no control, which may adversely affect its future results of operations, financial condition or stock price. The risk factors described in this Form 10-Q, as well as any cautionary language in this Form 10-Q, provide examples of risks, uncertainties and events that may cause the Company's actual results to differ materially from the expectations described in its forward-looking statements. You should be aware that the occurrence of any of the risks, uncertainties, or events described in this Form 10-Q could seriously harm Senetek's business and that, upon the occurrence of any of these events, the price of its securities could decline. All forward-looking statements included in this Form 10-Q are based on information available to the Company on the date hereof. Senetek assumes no obligation to update any such forward-looking statements except as may be required in connection with future reports of the Company pursuant to the Securities Exchange Act of 1934. Company Overview Senetek PLC is a life sciences company engaged in the research, development and commerciali...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Show all filings for SENETEK PLC /ENG/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for SENETEK PLC /ENG/ 10-Jun-2009Entry into a Material Definitive Agreement, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Show all filings for SENETEK PLC /ENG/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for SENETEK PLC /ENG/ 19-May-2009Entry into a Material Definitive Agreement, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "...Click here to read the whole Article (external link)
SENETEK PLC /ENG/ Files SEC form 10-Q, Quarterly Report
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Some of the information in this Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "may," "will," "should," "expect," "anticipate," "potential," "believe," "estimate," "intends" and "continue" or similar words. You should read statements that contain these words carefully because they: (i) discuss management's expectations about Senetek's future performance; (ii) contain projections of its future operating results or of its future financial condition; or (iii) state other "forward-looking" information. There will be events in the future that the Company is not able to predict or over which it has no control, which may adversely affect its future results of operations, financial condition or stock price. The risk factors described in this Form 10-Q, as well as any cautionary language in this Form 10-Q, provide examples of risks, uncertainties and events that may cause the Company's actual results to differ materially from the expectations described in its forward-looking statements. You should be aware that the occurrence of any of the risks, uncertainties, or events described in this Form 10-Q could seriously harm Senetek's business and that, upon the occurrence of any of these events, the price of its securities could decline. All forward-looking statements included in this Form 10-Q are based on information available to the Company on the date hereof. Senetek assumes no obligation to update any such forward-looking statements except as may be required in connection with future reports of the Company pursuant to the Securities Exchange Act of 1934. Company Overview Senetek PLC is a life sciences company engaged in the development of technologies that targ...Click here to read the whole Article (external link)
Would you like to leave a comment about Senetek plc SNKTY/SNKTY.OB
Find out what social network information about Senetek plc are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Senetek plc there is more great information available at Realpennies.com